Huaian

Familial hypercholesterolemia (FH) is an inherited condition that causes high levels of low-density lipoprotein cholesterol (LDL-C) and raises the risk for early coronary artery disease. This research aims to evaluate a child-parent screening program to identify children around 2 years old and their parents who carry FH mutations and are at high risk for inherited premature coronary artery disease. The study seeks to establish effective screening methods and techniques for early diagnosis of FH families to support future early intervention. The screening process includes three main steps: first, a capillary blood total cholesterol test using a finger blood sample from children aged around 2 years; second, a repeat cholesterol test for children with cholesterol levels above the 95th percentile; third, whole exome sequencing (WES) for children with cholesterol levels above the 99th percentile in the first two tests. Additionally, parents of children diagnosed with FH will undergo cholesterol and mutation tests. This is an observational study without any treatment interventions. Further treatment will be provided by Children's Hospital of Fudan University if needed. Participants will be children aged 1 to 3 years receiving routine child care. Researchers will assess total cholesterol levels and perform genetic testing to identify FH cases. Parents of affected children will also be tested. The main outcome measured is the affected status of familial hypercholesterolemia at enrollment. The study will help determine cholesterol percentiles in young children and the mutations contributing to high cholesterol. The total participation includes screening and testing steps, with follow-up treatment offered as appropriate.

This research investigates the safety and effectiveness of fospropofol disodium for injection during painless endoscopic diagnosis and treatment. The study focuses on adults aged 50 to 65 undergoing painless gastrointestinal endoscopy or colonoscopy. It compares fospropofol disodium to propofol, aiming to optimize anesthesia practices for stable induction, intraoperative circulation, and rapid recovery while reducing complications such as hypoxemia and cardiovascular events. Participants are randomly assigned to one of two groups: Group L receives slow intravenous sufentanyl combined with fospropofol disodium at 8 mg/kg, and Group B receives slow intravenous sufentanyl with propofol at 2 mg/kg. Both drugs are administered within 60 seconds by anesthesiologists. The study is multicenter, randomized, double-blind, and controlled, lasting over two years to gather comprehensive data. During the study, patients will be monitored for sedation success five minutes after anesthesia, duration of successful anesthesia induction, and occurrences of hypoxemia and other adverse events. Researchers will assess sedation quality, additional drug doses, intraoperative reactions, recovery quality, and any side effects. Participants and their families will complete rating scales, and safety will be closely observed throughout the process to support rapid postoperative recovery and reduce hospital costs.